AI chatbots aren’t therapists. But can they finally get men to open up?
Reported by STAT News · all stories from statnews.com
Editorial digest
While conversational software cannot replace licensed therapy, researchers are examining whether these digital tools can encourage more men to discuss their mental health. The report explores how synthetic dialog systems might lower traditional barriers to seeking support.
Digests are written in our own words from the publisher's headline — we never reproduce article text. Read the original for the full reporting.
Read the full story at STAT News →More like this
Other stories our editors tagged with the same themes.
- Trusted health newsroom11/5/2026
STAT+: As more doctors consult chatbots, health systems can block them — or buy in
Hospitals must choose whether to restrict or formally integrate conversational artificial intelligence tools increasingly utilized by physicians.
- Trusted health newsroom10/20/2026
STAT+: OpenEvidence’s JAMA paper leaves open questions
A recent journal publication regarding OpenEvidence still leaves several unanswered questions in medical technology.
- Trusted health newsroom11/8/2026
STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype
Recent setbacks in cardiovascular medication trials highlight the need for caution regarding artificial intelligence promises in medicine.
- Trusted health newsroom10/13/2026
STAT+: Takeaways from an evaluation of Google’s diagnostic chatbot, AMIE
An assessment of Google's diagnostic AI chatbot, AMIE, has provided key findings.
- Trusted health newsroom10/30/2026
STAT+: FDA, CMS scramble to avoid regulatory logjam as more states look to test AI in clinical settings
Federal health agencies are working quickly to prevent oversight bottlenecks as states prepare clinical artificial intelligence trials.
- Trusted health newsroom10/22/2026
STAT+: Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction
Virtual clinics are providing off-label GLP-1 therapies for substance use disorders before receiving formal regulatory authorization.